Clinical Trials
24 trialsNCT01216176 2025-01-08
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
University of Miami
Phase 1/2 Completed
NCT00265876 2023-08-04
AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT00752206 2020-01-18
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Sarcoma Alliance for Research through Collaboration
Phase 2 Terminated
NCT00397878 2019-08-20
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00735917 2019-04-02
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00638937 2018-08-29
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00607594 2018-08-23
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00659360 2018-06-29
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00513071 2018-04-19
AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT02085603 2018-04-13
SarCaBon
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Completed
NCT00528645 2017-12-07
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02116712 2016-11-30
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Baylor College of Medicine
Phase 1 Completed
NCT00718809 2015-06-10
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01196741 2015-05-05
SaPPrOC
University College, London
Phase 2/3 Completed
NCT01267266 2015-04-01
Saracatinib in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00669019 2014-05-21
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00513435 2014-04-30
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00559507 2014-04-30
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00558272 2013-05-27
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
AstraZeneca
Phase 2 Completed
NCT00610714 2012-12-18
OVERT-1
AstraZeneca
Phase 2 Completed
NCT00704366 2011-05-16
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00496028 2010-09-22
Phase I Study in Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00475956 2010-04-15
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT01000896 2010-02-04
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
AstraZeneca
Phase 1 Withdrawn